Literature DB >> 35353239

OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression.

Shuai Yang1,2, Jiangang Zhang1, Yanquan Xu1, Jingchun Wang1, Huakan Zhao3,4, Juan Lei3,4, Yu Zhou3,4, Yu Chen3,4, Lei Wu3,4, Mingyue Zhou3,4, Lu Zheng5, Xiaohui Ji6,7, Yongsheng Li8,9,10.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality; however, effective immunotherapy strategies are limited because of the immunosuppressive tumor microenvironment. Macrophages are essential components of the HCC microenvironment and are related to poor prognosis. Here, we evaluated the attributes of paracancer tissues in tumor immunity and progression using public databases. Based on the abundance of immune cells estimated by CIBERSORT, we performed weighted gene co-expression network analysis and found a specific module associated with M2 macrophages. Through analyzing interaction networks using Cytoscape and public datasets, we identified oncoprotein-induced transcript 3 (OIT3) as a novel marker of M2 macrophages. Overexpression of OIT3 remodeled immune features and reprogrammed the metabolism of M2 macrophages. Moreover, compared with wildtype macrophages, OIT3-overexpressing macrophages further enhanced the migration and invasion of co-cultured cancer cells. Additionally, OIT3-overexpressing macrophages promoted tumorigenesis and cancer development in vivo. Taken together, the findings demonstrate that OIT3 is a novel biomarker of alternatively activated macrophages and facilitates HCC metastasis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alternatively activated macrophages; Hepatocellular carcinoma; Migration and invasion; OIT3; Paracancer; Weighted gene co-expression network analysis

Mesh:

Substances:

Year:  2022        PMID: 35353239     DOI: 10.1007/s00262-022-03188-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  36 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

Review 2.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

3.  Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium.

Authors:  Kelly Graham; Xijin Ge; Antonio de Las Morenas; Anusri Tripathi; Carol L Rosenberg
Journal:  Clin Cancer Res       Date:  2010-11-08       Impact factor: 12.531

4.  Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma.

Authors:  Oscar W H Yeung; Chung-Mau Lo; Chang-Chun Ling; Xiang Qi; Wei Geng; Chang-Xian Li; Kevin T P Ng; Stuart J Forbes; Xin-Yuan Guan; Ronnie T P Poon; Sheung-Tat Fan; Kwan Man
Journal:  J Hepatol       Date:  2014-10-30       Impact factor: 25.083

5.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

7.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

Review 8.  Tumor Immunology and Tumor Evolution: Intertwined Histories.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Immunity       Date:  2020-01-14       Impact factor: 31.745

Review 9.  New advances in the diagnosis and management of hepatocellular carcinoma.

Authors:  Ju Dong Yang; Julie K Heimbach
Journal:  BMJ       Date:  2020-10-26

10.  Comprehensive analysis of normal adjacent to tumor transcriptomes.

Authors:  Dvir Aran; Roman Camarda; Justin Odegaard; Hyojung Paik; Boris Oskotsky; Gregor Krings; Andrei Goga; Marina Sirota; Atul J Butte
Journal:  Nat Commun       Date:  2017-10-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.